4 documents

Compugen reacquired Baize's stakes in mAbs against undisclosed cancer targets discovered by Compugen and undisclosed compounds from Compugen's Pipeline Program. In exchange, Baize will receive 1.6 million Compugen shares and will be eligible for up...

Compugen will receive $8 million in R&D funding from investment firm Baize Investments Ltd. to support Compugen's Pipeline Program, which consists of more than 30 mAbs and proteins for cancer and autoimmune indications. In exchange...

Compugen Ltd. has spent more than a decade developing and refining its in silico prediction platform to discover novel peptides and proteins that can be developed as therapeutics or targets. The company has neither the...

Compugen received $5 million in R&D funding from investment firm Baize Investments Ltd. to support Compugen's Pipeline Program, which consists of more than 30 mAbs and proteins in discovery and preclinical testing for cancer, autoimmune...